News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Drew Moghanaki: ‘Some pembrolizumab’ is better than ‘No pembrolizumab’ in patients scheduled for preop chemo
Drew Moghanaki/X
Jan 3, 2025, 12:45

Drew Moghanaki: ‘Some pembrolizumab’ is better than ‘No pembrolizumab’ in patients scheduled for preop chemo

Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA, shared a post by Jonathan Spicer, Medical Director of the McGill Thoracic Oncology Program, on X:

“With this practice-changing study we learned that ‘some pembro’ is better than ‘no pembro’ in patients scheduled for preop chemo.

Yet, by my no means does it confirm that ‘more pembro’ after surgery further helps already-responders (MPR and pCR) or non-responders.”

Quoting Jonathan Spicer’s post:

“KN671 OS and HRQoL!

Check it out.”

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Jonathan D Spicer, Marina C Garassino, Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Prof Se-Hoon Lee, Prof Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gastón L Martinengo, Prof Olivier Bylicki, Delvys Rodríguez-Abreu, Jamie E Chaft, Prof Silvia Novello, Jing Yang, Ashwini Arunachalam, Steven M Keller, Ayman Samkari, Shugeng Gao

Drew Moghanaki

Ashwini Arunachalam Ayman Samkari cancer chemotherapy Christophe Dooms Delvys Rodriguez Abreu Drew Moghanaki Ekkehard Eigendorff Gastón L Martinengo Jamie E Chaft Jing Yang Jonathan D. Spicer Jonathan Spicer Margarita Majem Moishe Liberman OncoDaily Oncology pembrolizumab Prof Heather Wakelee Prof Ke-Neng Chen Prof Marina C Garassino Prof Masahiro Tsuboi Prof Olivier Bylicki Prof Se-Hoon Lee Prof Silvia Novello Steven M Keller Terufumi Kato
Special Coverage
Science
Jan 3, 2025, 12:51
Targeting Molecular Pathways to Control ICI Toxicities
Insight
Jan 3, 2025, 12:45
Drew Moghanaki: ‘Some pembrolizumab’ is better than ‘No pembrolizumab’ in patients scheduled for preop chemo
Insight
Jan 3, 2025, 12:40
Senthil Kumar: First-Line Therapy in RCC, Expanding Choices in a New Era
Insight
Jan 3, 2025, 12:36
Akhil Santhosh: Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
Blog
Jan 3, 2025, 12:34
Here’s to another year of collaboration, progress, and making a difference - AIM-HI Accelerator Fund
Blog
Jan 3, 2025, 12:33
Stephen H Bradley: Roy Castle Lung Cancer Foundation recommendations on improving symptomatic lung cancer
Blog
Jan 3, 2025, 12:30
Emad Shash: Wishing everyone a joyful and hopeful start to 2025
Blog
Jan 3, 2025, 12:29
Michael Gieske: Rewarding to join my friends in presenting Mass General Hospital Grand Rounds
Insight
Jan 3, 2025, 12:28
Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond - SPCC
Insight
Jan 3, 2025, 12:23
A New Year’s message from the Head of the Yeolyan Hematology and Oncology Center
Blog
Jan 3, 2025, 12:21
Bente Mikkelsen: Integrating cancer into crisis
Insight
Jan 3, 2025, 12:20
Amol Akhade: Progress made in outcomes of metastatic cervical cancer over the years